Search

Displaying results 511 - 520 of 4627 in total
  1. Drug

    Ebola Zaire vaccine (live, attenuated)

    go.drugbank.com/drugs/DB15595
    ApprovedInvestigational

    [L10854] Ebola virus disease, formerly known as Ebola hemorrhagic fever, is a rare but severe and often deadly disease. … In December 2019, Ervebo was approved by the FDA in the United States.

  2. Drug

    Furosemide

    go.drugbank.com/drugs/DB00695
    ApprovedInvestigationalVet approved

    [L7961] It mainly works by inhibiting electrolyte reabsorption from the kidneys and enhancing the excretion of water from the body. … [L7958] Furosemide is used for edema secondary to various clinical conditions, such as congestive heart failure exacerbation, liver failure, renal failure, and high blood pressure.

    Categories: High-Ceiling Diuretics, High-Ceiling Diuretics and Potassium-Sparing Agents
  3. Drug

    Nafcillin

    go.drugbank.com/drugs/DB00607
    ApprovedInvestigational

    It is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strains that are resistant to other penicillins, except those caused by MRSA.

  4. Drug

    Chloroprocaine

    go.drugbank.com/drugs/DB01161
    ApprovedInvestigational

    Both can be given as intrathecal injections for peripheral and central nerve block, but only the preservative-free formulation can be used for lumbar and caudal epidural blocks. … [A252952,L43382] Topical chloroprocaine for ophthalmic use was approved by the FDA in September 2022 for ocular surface anesthesia.[L43387]

  5. Drug

    Daptomycin

    go.drugbank.com/drugs/DB00080
    ApprovedInvestigational

    [A231384] Early work on developing daptomycin was abandoned due to observed myopathy but was resumed in 1997 when Cubist Pharmaceuticals Inc. licensed daptomycin; it was found that a once-daily dosing … [A231379] Daptomycin was approved by the FDA on September 12, 2003, and is marketed under the name CUBICIN® by Cubist Pharmaceuticals LLC (Merck & Co.).[L32534]

  6. Drug

    Idebenone

    go.drugbank.com/drugs/DB09081
    ApprovedInvestigational

    Due to its biochemical mode of action, it's thought that idebenone may re-activate viable-but-inactive retinal ganglion cells (RGCs) in LHON patients [L885]. … It is not currently approved for use by either the Food and Drug Administration (USA) or Health Canada.

  7. Drug

    Cefdinir

    go.drugbank.com/drugs/DB00535
    ApprovedInvestigational

    Cefdinir was approved by the FDA in 1997 to treat a variety of mild to moderate infections and was initially marketed by Abbvie.

  8. Drug

    Bicisate

    go.drugbank.com/drugs/DB11164
    Approved

    [A32374] The complex of bicisate and technetium Tc99m as a kit was developed by Lantheus Medcl and FDA-approved on November 23, 1994.[L2029]

  9. Drug

    Suvorexant

    go.drugbank.com/drugs/DB09034
    ApprovedInvestigational

    Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.

  10. Drug

    Erythromycin

    go.drugbank.com/drugs/DB00199
    ApprovedInvestigationalVet approved

    [L5245] Erythromycin is widely used for treating a variety of infections, including those caused by gram-positive and gram-negative bacteria. … Erythromycin is a bacteriostatic antibiotic drug produced by a strain of Saccharopolyspora erythraea (formerly Streptomyces erythraeus) and belongs to the macrolide group of antibiotics which consists